Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA™, a breakthrough drug for treating acute central nervous system conditions, announced that a prospective multi-center open-label pilot study of CIRARA in patients with acute traumatic cervical spinal cord injuries.
{iframe}http://www.umventures.org/news/remedy-pharmaceuticals-initiates-phase-2a-study-cirara™-spinal-cord-injury{/iframe}